In the past hundred years, synthetic drugs had gradually replaced plant-derived drugs, except for antibiotics and antitumor drugs. Due ; ; to the development of expérimentation with molécules, new openings and perspectives appear for natural products. Progress in bio-\ i technology, biochemistry and research on metabolism are also the cause of renewed interest in natural resources. [ of diseases are also présent in our food. The food-processing îndustry is heavily investing in this branch, which results in an improve-,' ment of the overall quality of our diet, including the development of functional food and neutraceuticals.
Introduction
Pharmacognosy was for the first time defined as a pharmaceutical discipline in 1815 bySeidler (Through A. Tschirch, 1 909). Tschirch gave the following définition (translated from German): " With the name Pharmacognosy we mean the science which has the task to learn everything about drugs originating from plants or animais in ail aspects, except the physiological effect, to describe them correctly and under a gênerai vision connect this knowledge". During the 1 9th century it was by far the most important pharmaceutical discipline, the "mother" of ail présent day pharmaceutical disci¬ plines. But 100 years ago (1899) the first signs for a new era be¬ came obvious with the introduction of a very successful synthetic drug: Aspirin (Viktorin, 1 999). The first example of using nature as lead for a new synthetic drug. Despite some obvious failures, such as heroin, gradually synthetic chemistry became more important for developing new drugs. The wish to hâve pharmaceutical formula¬ tions with single pure compounds with well defined activities was an important driving force in this trend.
Pharmacognosists hâve always been very keen in introducing new technologies into their discipline. In the 1 9th century microscopy was introduced for the quality control of pharmaceutical prépara¬ tions from plants. However, for too many years pharmacognosy re¬ mained with thèse methods, and with the rapidly decreasing number of herbal préparations in the pharmacy, the discipline had great difficulties in holding their prominent position in the pharma¬ ceutical curriculum in the sixties and seventies. Fortunately, some visionary pharmacognosists were able to open up new directions. The development of thin layer chromatography by the well known pharmacognosist professor Egon Stahl is probably the best ex¬ ample (Stahl, 1 967) . But also in the field of gas chromatography and high pressure liquid chromatography, pharmacognosists were among the pioneers in the analysis of plant materials. For studies of the active compounds in plants, thèse chromatographie methods became important tools. Moreover, in the seventies the spectro¬ metric methods such as MS and NMR became commonplace for the pharmacognosists in their search for new biologically active com¬ pounds in plants. But in that period developing new drugs from plants was not as easy as with synthetic drugs, as the pharmaco¬ logical test Systems, mainly in vivo animal experiments and in-vitro isolated organs, are not suited for bioassay-guided fractionation of active compounds from plant extracts. That requires methods that can readily measure large numbers of samples in a short time. Only for activities for which simple test methods were available, natural products remained a major source for new drugs. This is clearly illustrated by the fact that most of the antibiotics and antitumor drugs are natural products (Cragg et terest was also clearly reflected in the meeting of the four major in¬ ternational societies in the field of pharmacognosy and natural products research. This joint meeting, a 5-yearly event, in July 1 999 attracted more than 1 100 scientists from ail over the world to Amsterdam, the largest number ever in this field and almost double the number of the previous meeting 5 years ago.
There are several reasons which can be mentioned to explain the increased interest in natural products and pharmacognosy: search for new leads for drug development biotechnology for the production of pharmaceuticals health daims for food (nutraceuticals) validation of traditional medicines increased interest in phytotherapy With this development in the past décade presently we can distin¬ guish three major areas of interest for the pharmacognosist: studies of new biologically active natural products production of drugs from natural origin, including new me¬ thods such as biotechnology quality control of drugs from natural origin.
The two first aspects I should like to discuss in some more détail. The studies for new active compounds hâve two major aspects: finding new leads for drug development and studies on the validation of traditional medicines. Traditionally the pharmacognosists hâve focused on plants as the source for new compounds, whereas work on microorganisms has mostly been in the hands of industry or ac¬ adémie chemistry groups. Hère I will also mainly deal with plants.
Leadfinding
Nature is an almost infinité source for drug development. The number of organisms that exist in the world is not so easy to assess. Pimm et al. (1 995) made an effort to express biodiverstity in num¬ bers. The total number of species is estimated to be between 1 0 1 00 million. The largest diversity is in insects (total of arthropods esti¬ mated as high as 30 million species), algae, prokaryotes and fungi (each about 1 ,5 million species). Plants are in fact a relatively small group with about 250 000 species, of which about 6% has been studied for one or more biological activities, and about 1 5% has been studied phytochemically (Verpoorte 1998) . Ail of thèse or¬ ganisms produce a number of secondary metabolites which are connected with the interaction of the organism with its environment. During évolution this has resulted in a large chemodiversity (Harborne, 1978 Hall, 1 999) is a compilation of ail known compounds and has now about 1 39 000 entries. As you can learn from Table 1 , the major group is that of terpenoids, the second major group is that of the al¬ kaloids. Particularly the latter group contains a large number of medicines. This is due to their spécial characteristic of a water sol¬ uble compound under acidic conditions and lipophilic properties under neutral and basic conditions. In fact quite a large proportion of ail medicines do contain a tertiary nitrogen. (Oosterkamp et ai, 1997a, b Besides the more or less at random screening of organisms for bio¬ logical activity, one can also look at ecological leads for a biolog¬ ical activity (Verpoorte, 1998; . E.g. young leaves and seedlings are expected to be more strongly protected against pred¬ ators by, among others, secondary metabolites, than older parts of a plant. For example, we found very high levels of quinoline alka¬ loids (quinine and related compounds) in seedlings of Cinchona (Aerfs et ai, 1990; 1991a,b) and the highest level of ginkgolides ever found, we detected in seedlings of Ginkgo biloba (Carrier et ai, 1998 Sato et ai, 1982; (Zaprometov, 1988a, b) and anthraquinones in Rubia fruticosa cell cultures (Schulte et ai, 1984 The first point was considered as a major constraint. Shear forces in stirred bioreactors were thought to be a major problem for the Some commercial successes hâve been achieved, such as the pro¬ duction of shikonin (Fuyita and Tabata, 1 987), the production of ginseng roots biomass and some polysaccharides préparations (Fu et ai, 1999; Hibion and Ushiyama, 1999) . However, for the most interesting compounds such as hyoscyamine, morphine, quinine and vinblastine, the productivity was too low, or even zéro (Verpoorte et ai, 1991 Cunningham and Porter, 1 998; Ma and Hein, 1996; Whitelam and Cockburn,1996) . It opens the way for the production of antibodies for a very low price, opening ail kind of new applications. The use in caries prévention is an example of the potential applications of such antibodies.
Low molecular compounds
The genetic engineering can also be applied to improve the yield of low molecular weight compounds in the producing organisms, e.g.
penicillin. I will briefly give some examples of genetic engineering concerning plant derived pharmaceuticals. Three possibilities can be envisaged:
increasing the production of a compound in plant or plant cell culture producing plant compound in microorganism production of a new compound in a plant or plant cell culture Increasing the production of a plant secondary metabolite The production of secondary metabolites can be regulated in dif¬ férent ways: the flux towards the compound might be regulated through the activity of enzymes involved or by feedback inhibition.
The carbon flux may be diverted into compétitive pathways. The product level may also be affected by catabolism of the secondary metabolite (Dagnino et ai, 1994; Dos Santos et ai, 1994; Schripsema et ai, 1994) . Compétitive pathways and catabolism can be blocked by introducing antisense gènes for the gènes en¬ coding the enzymes concerned.
By identifying possible limiting steps in biosynthetic pathways, one can subsequently clone the gène encoding the enzyme involved and overexpress this enzyme or use gènes from other sources to overcome the limitation. We hâve shown that it is feasible to overexpress tryptophan decarboxylase and strictosidine synthase, two important gènes from the terpenoid indole alkaloids, in cell cultures of various plants. In Catharanthus roseus cell cultures, the overexpression of thèse endogenous gènes leads to increased level of enzyme activity, but only with the latter gène some increase in the alkaloid produc¬ tion was observed (Canel et ai, 1998) . Expression in tobacco cells results in the production of tryptamine (Hallard et ai, 1 997; Leech et ai, 1 999) and after feeding secologanin also in the production of strictosidine (Hallard et ai, 1997) . Thèse results show that it is feasible to engineer secondary metabolite pathways of pharmaceutically important compounds, however, the increases mainly concern the immédiate product of the overexpressed enzyme. A promising option is the cloning of regulatory gènes of a pathway and overexpression of thèse (Grotewold et (Oosterkamp et ai, 1997a, b) . Nous avons aussi développé une méthode du même type pour la détection de l'inhi¬ bition de I'acétylcholinestérase dans des extraits de plantes (Ingkaninan et ai, résultats non publiés). En employant des méth¬ odes de préfractionnement, la probabilité de trouver des composés nouveaux sera augmentée et la "dereplication", c'est-à-dire l'iden¬ tification rapide des composés actifs connus ou les faux-positifs, prendra moins de temps. On a pu remporter quelques succès commerciaux, par exemple la production de shikonine (Fuyita & Tabata, 1 987), la production de la biomasse de racines de ginseng et certaines préparations de polysaccharides (Fu et ai, 1999 ; Hibion & Ushiyama, 1999) .
Cependant, pour les composés les plus intéressants, tels que la hyoscyamine, la morphine, la quinine et la vinblastine, la produc tivité est restée faible, voire nulle (Verpoorte ef ai, 1991 (Hain et ai, 1990 ; , et l'introduction du gène de l'hyoscyamine 6-hydroxylase dans YAtropa belladonna, ce qui a pour résultat de faire produire de la scopolamine au lieu de l'hyoscyamine (Hashimoto et ai, 1994 ; Yun et ai, 1992 
